Themis Medicare Ltd
Themis Medicare Ltd Q3 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q3 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Themis Medicare Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 FY25 Net Revenue: Rs. Q3 FY25 EBITDA: Rs.
From Themis Medicare Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY25 Net Revenue: Rs. 93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. 82.51 Cr in Q3 FY24 (Page 9).
- 9M FY25 Net Revenue: Rs. 333.81 Cr, a 17.56% YoY increase from Rs. 283.94 Cr in 9M FY24 (Page 10).
- Formulation segment growth Q3 FY25: 22% YoY (Page 9).
- Hospital Business growth Q3 FY25: over 20% YoY (Page 9).
- Trade business growth Q3 FY25: approximately 37% YoY (Page 9).
- Management outlook (Page 6): Continuous growth expected, with efforts to expand hospital business and new product launches planned for commercial launch by Q4 FY 2025-26.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The presentation mentions plans to enhance already built-in capacity to increase productivity (Page 6, Management Comment).
- No specific capex amounts or detailed timelines for capacity expansion or new plants/projects are provided explicitly in the presentation.
- The company highlights state-of-the-art manufacturing facilities at Haridwar (Formulations) and Hyderabad and Vapi (Synthetic APIs) with annual capacities listed but does not specify new expansions or projects (Page 15).
- There is ongoing R&D investment with figures given for FY19-20 to 9M FY25 but these relate to product development rather than capex (Page 16).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Themis Medicare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key investor presentation takeaways from Wockhardt Ltd's Q3 FY25 investor presen
- NGL Fine Chem Ltd (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key investor presentation takeaways from NGL Fine Chem Ltd's Q
- Shree Ganesh Remedies Ltd (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 investor presentation — and how it ra
- Lincoln Pharmaceuticals Ltd (Q3 FY25)
EBITDA:** ₹32.2 crore, up 16% year-on-year. Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q3 FY25 investor presentation — and how it ra
Frequently Asked Questions
What were Themis Medicare Ltd Q3 FY25 results?
Q3 FY25 Net Revenue: Rs. Q3 FY25 EBITDA: Rs.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Is Themis Medicare Ltd planning capital expenditure?
The presentation mentions plans to enhance already built-in capacity to increase productivity (Page 6, Management Comment).
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.